Isotope

Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

Retrieved on: 
Tuesday, September 27, 2022
Research, FDA, Clinical Trials, Radiology, Health, Pharmaceutical, General Health, Science, Oncology, Safety, Blood, Patient, Clinical trial, Agency, Physician, Prostate cancer, Prostate-specific antigen, Disease, Death, Technical University of Munich, COVID-19, Magnetic resonance, Food, Company, Acquisition, MRCP, NDA, PET, Nuclear medicine, Institute of technology, Ageing, Natural history, Man, Molecular imaging, FRCR, PSA, BCR, Risk, FDA, MBBS, Neoplasm, Cardiac catheterization, PSMA, Health, Apical membrane antigen 1, Membrane, CEUS, Isotope, Radiopharmaceutical, MRI, Magnetic resonance imaging, Therapy, 3D ultrasound, Lymph, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Interventional radiology, Cancer, Prognosis, Google Images, Male, Solution, Multimedia, Recurrence, Medical imaging

The submission is for the use of 18F-rhPSMA-7.3 PET for diagnostic imaging of prostate cancer.

Key Points: 
  • The submission is for the use of 18F-rhPSMA-7.3 PET for diagnostic imaging of prostate cancer.
  • Subject to FDA approval, we believe that 18F-rhPSMA-7.3 PET imaging may be clinically useful in the management of men affected by prostate cancer across the care continuum.
  • Blue Earth Diagnostics Phase 3 LIGHTHOUSE trial assessed the safety and diagnostic performance of 18F-rhPSMA-7.3 PET in men with newly diagnosed prostate cancer in 356 patients.
  • Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of death worldwide.

Cambridge Isotope Laboratories, Inc. (CIL) Partners With ISOtopic Solutions to Release the New Stable Isotope-Labeled and Unlabeled Crude Lipid Yeast Extracts

Retrieved on: 
Monday, September 26, 2022
Isotope, Cat, Organic acid, University, Canada, Intention, Mass spectrometry, CIL, Otsuka Pharmaceutical, CEO, OLED, Solution, Lipidomics, Biomass, Research, GLOBE, ABX, Lipid, Deuterium, Lithium, Aluminium, Xenia

TEWKSBURY, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts.

Key Points: 
  • TEWKSBURY, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts.
  • Andrew goes on to say: "A major benefit of the stable isotope-labeled lipid yeast extract is that the fatty acids and lipids are uniformly 13C-labeled at highisotopic enrichment.
  • To learn more about these new Crude Lipid Yeast Extracts, as well as the established Metabolite Yeast Extracts (Cat nos.
  • The ISOtopic Solutions product line consists of stable isotope-labeled biomolecules and labeled biomass for the standardization and validation of mass spectrometric analysis methods.

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Isotope, Half-life, Peptide, Nuclear pharmacy, Database administrator, Therapy, Safety, Radiation, Molecular imaging, Clovis Oncology, Sarcoma, FDA, FAP, SNMMI, Neoplasm, Antibody, Company, Population, Cancer, Private Securities Litigation Reform Act, Isotopia Festival, EANM, U.S. Securities and Exchange Commission, Program, Patient, Colon, CEO, Oncology, Gallium, Cell, Fibroblast, Radionuclide, NCT, NASDAQ, CAFS, Research, Security (finance), Congress, Mesothelioma, BD, GMP, EMA, View, Drug discovery, TRT, Pharmaceutical industry, Medical imaging

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement further secures our ability to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.
  • Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security, said Keren Moshkoviz, Deputy CEO and BD at Isotopia.

Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical Isotope

Retrieved on: 
Tuesday, September 20, 2022
Isotope, Cancer, ASX, CEO, Medicine, SHINE, Multimedia, Pharmaceutical industry, Medical imaging

JANESVILLE, Wis. and SYDNEY, Sept. 19, 2022 /PRNewswire/ -- SHINE Technologies, a next-generation fusion technology company, and Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced that they have entered into a clinical supply agreement. SHINE will supply Radiopharm with isotope non-carrier-added lutetium-177 (Lu-177).

Key Points: 
  • SHINE will supply Radiopharm with isotope non-carrier-added lutetium-177 (Lu-177).
  • The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products.
  • "We are excited that our isotopes will play a critical role in Radiopharm Theranostics' programs that aim to revolutionize cancer treatment."
  • "Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs unimpeded," said Riccardo Canevari, CEO and managing director of Radiopharm Theranostics.

BWXT Medical Submits Tc-99m Generator New Drug Application to FDA

Retrieved on: 
Tuesday, September 13, 2022
Defense, Aerospace, Manufacturing, Energy, Nuclear, Other Defense, People, Isotope, Health, United States Department of Energy, Molybdenum, Nuclear medicine, NYSE, Twitter, FDA, BWXT, Food, Form 10-K, Environment, U.S. Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Risk, Technology, Fortune 1000, Google Images, BWX Technologies, Investor relations, Security (finance), Ontario Power Generation, NASA, Hospital, Annual report, Uranium, Defense News, Pharmaceutical industry, Renewable energy, Medical device

BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has submitted a new drug application to the U.S. Food and Drug Administration (FDA) to request approval of its technetium-99m (Tc-99m) generator for diagnostic imaging.

Key Points: 
  • BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has submitted a new drug application to the U.S. Food and Drug Administration (FDA) to request approval of its technetium-99m (Tc-99m) generator for diagnostic imaging.
  • Alternatively, the BWXT Tc-99m generator will be produced from natural molybdenum targets irradiated at a commercial power reactor, greatly reducing complex waste by-products.
  • Our Tc-99m generator product is a lower cost, more reliable, drop-in replacement to current generators, and we see it as a key component of our medical portfolio.
  • BWXT has published a presentation on the Investor Relations section of its website about BWXT Medical.

Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 7, 2022
AstraZeneca, Tat, DNA, IND, View, Neurotensin receptor, Morgan, NTSR1, TRIUMF, Isotope, Multimedia, Pembrolizumab, Corporate communication, Conference, Company, FDA, Neoplasm, Merck, Webcast, FGFR3, Patient, Pharmaceutical industry, Fusion

HAMILTON, ON and BOSTON, Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference onWednesday, September 14, 2022at12:55 p.m.

Key Points: 
  • HAMILTON, ON and BOSTON, Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference onWednesday, September 14, 2022at12:55 p.m.
  • A replay of the webcast will be archived on the Company's website for 60 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors.

Insights on the Stable Isotope Labeled Compounds Global Market to 2026 - Stable Isotope Studies Aid in Integration of Non-essential Amino Acids in Pea Aphids - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Chemicals, Plastics, Science, Research, Manufacturing, Metabolomics, Cancer, Research, Toxicity, Deuterium, Metal toxicity, Incidence, Isotope, Mass spectrometry, CAGR, Therapy, Diabetes, NMR, Growth, Metabolism, Proteomics, Patient, Lithium

The "Stable Isotope Labeled Compounds - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stable Isotope Labeled Compounds - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Stable isotope labelling comprises the use of non-radioactive isotopes which can act as tracers employed to model various chemical and biochemical systems.
  • Aside from their use in metabolomics research, stable isotope-labeled compounds are finding use in medical diagnostic research, proteomics, and environmental analysis.
  • Stable isotope labeled compounds is witnessing growing use in metabolism mediated toxicity research.

AdvanCell Closes A$18M Series B Funding Led by Morningside

Retrieved on: 
Wednesday, August 24, 2022
Research, Men, Biotechnology, Radiology, General Health, Pharmaceutical, Consumer, Health, Science, Oncology, Radiochemistry, Hamstringing, Technology, CEO, Research, Federal, Alpha particle, Director, Board, Chair, Course, Isotope, Social responsibility, Targeted alpha-particle therapy, Australian Nuclear Science and Technology Organisation, Company, Research and Development Tax Incentive, Element, Coronavirus Scientific Advisory Board (Turkey), ANSTO, Founder, Alpha, Growth, Adoption, Patient, Pharmaceutical industry, Management, Medical imaging, Cancer

AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.

Key Points: 
  • AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
  • AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options.
  • AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board.
  • For more information visit www.advancell.com.au
    Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm.

Picarro Introduces the First Automated Solution for Continuous Ethylene Oxide Monitoring

Retrieved on: 
Wednesday, August 17, 2022
Zero, CEMS, CRDS, PPT, Ethylene oxide, Technology, EPA, Method, ETO, Engineering, EO, Marketing, Gaps, Maintenance, Isotope, GHG, Sterilization, Cavity ring-down spectroscopy, Solution, Cavity, Environmental remediation

SANTA CLARA, Calif., Aug. 17, 2022 /PRNewswire/ -- Picarro Inc., a leading gas analytics company, today announced the first comprehensive solution for monitoring ambient levels of Ethylene Oxide (EtO or EO) at community monitoring stations and industrial fencelines. With this system, air quality networks, medical sterilization facilities, and petrochemical plants will be able to monitor and quantify low, ambient levels of EtO for months – a capability that is critical to understanding long-term exposure to this carcinogenic air pollutant. As the EPA launches a community engagement effort to publicize its long-anticipated rule change impacting commercial sterilization facility EtO emissions, Picarro is introducing this solution to replace insufficient legacy monitoring systems.

Key Points: 
  • SANTA CLARA, Calif., Aug. 17, 2022 /PRNewswire/ -- Picarro Inc. , a leading gas analytics company, today announced the first comprehensive solution for monitoring ambient levels of Ethylene Oxide (EtO or EO) at community monitoring stations and industrial fencelines.
  • Leveraging Picarro's advanced Cavity Ring-Down Spectroscopy (CRDS), the Picarro Ambient Air Monitoring System for EtO offers several unique advantages.
  • "With our new automated solution, customers can have confidence in their ability to precisely monitor extremely low levels of ethylene oxide for months at a time."
  • The Ambient Air Monitoring System for EtO , comprised of the G2920 and Zero Reference Module, improves detection limits and enables long-term, automated monitoring.

Picarro Introduces the First Automated Solution for Continuous Ethylene Oxide Monitoring

Retrieved on: 
Wednesday, August 17, 2022
Zero, CEMS, CRDS, PPT, Ethylene oxide, Technology, EPA, Method, ETO, Engineering, EO, Marketing, Gaps, Maintenance, Isotope, GHG, Sterilization, Cavity ring-down spectroscopy, Solution, Cavity, Environmental remediation

SANTA CLARA, Calif., Aug. 17, 2022 /PRNewswire/ -- Picarro Inc., a leading gas analytics company, today announced the first comprehensive solution for monitoring ambient levels of Ethylene Oxide (EtO or EO) at community monitoring stations and industrial fencelines. With this system, air quality networks, medical sterilization facilities, and petrochemical plants will be able to monitor and quantify low, ambient levels of EtO for months – a capability that is critical to understanding long-term exposure to this carcinogenic air pollutant. As the EPA launches a community engagement effort to publicize its long-anticipated rule change impacting commercial sterilization facility EtO emissions, Picarro is introducing this solution to replace insufficient legacy monitoring systems.

Key Points: 
  • SANTA CLARA, Calif., Aug. 17, 2022 /PRNewswire/ -- Picarro Inc. , a leading gas analytics company, today announced the first comprehensive solution for monitoring ambient levels of Ethylene Oxide (EtO or EO) at community monitoring stations and industrial fencelines.
  • Leveraging Picarro's advanced Cavity Ring-Down Spectroscopy (CRDS), the Picarro Ambient Air Monitoring System for EtO offers several unique advantages.
  • "With our new automated solution, customers can have confidence in their ability to precisely monitor extremely low levels of ethylene oxide for months at a time."
  • The Ambient Air Monitoring System for EtO , comprised of the G2920 and Zero Reference Module, improves detection limits and enables long-term, automated monitoring.